Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Liabilities and Shareholders Equity: 2022-2024

Historic Liabilities and Shareholders Equity for Gossamer Bio (GOSS) over the last 3 years, with Dec 2024 value amounting to $315.3 million.

  • Gossamer Bio's Liabilities and Shareholders Equity fell 40.49% to $208.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year decrease of 19.29%. This contributed to the annual value of $315.3 million for FY2024, which is 1.08% up from last year.
  • Gossamer Bio's Liabilities and Shareholders Equity amounted to $315.3 million in FY2024, which was up 1.08% from $311.9 million recorded in FY2023.
  • In the past 5 years, Gossamer Bio's Liabilities and Shareholders Equity registered a high of $315.3 million during FY2024, and its lowest value of $272.4 million during FY2022.
  • Over the past 3 years, Gossamer Bio's median Liabilities and Shareholders Equity value was $311.9 million (recorded in 2023), while the average stood at $299.9 million.
  • Data for Gossamer Bio's Liabilities and Shareholders Equity shows a peak YoY grew of 14.49% (in 2023) over the last 5 years.
  • Gossamer Bio's Liabilities and Shareholders Equity (Yearly) stood at $272.4 million in 2022, then increased by 14.49% to $311.9 million in 2023, then rose by 1.08% to $315.3 million in 2024.